Please assess the completion status of the following clinical trial:

Trial Title: High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Crohn's disease involving predominantly the ileum and/or cecum. The diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. The diagnosis must have been confirmed by at least one gastroenterologist.~* Harvey Bradshaw Index of at least 7~* The onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. Symptoms relating to the flare should not have diminished or started to improve prior to entry.~* Written informed consent~Exclusion Criteria:~* Concomitant corticosteroids, including budesonide~* Corticosteroids within the previous 2 months~* Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months~* Maintenance infliximab, or infliximab or other biologics in the preceding 3 months~* Change in dose during previous 4 weeks in 5-aminosalicylate, probiotic and/or antibiotic, or in chronic azathioprine, 6-mercaptopurine, or methotrexate~* If currently using azathioprine, 6-mercaptopurine or methotrexate, these must have been used steadily for at least 4 months~* Current experimental drugs or experimental drugs within the last 3 months~* If the severity of the flare has started to decrease spontaneously~* Coexisting diagnosis of primary sclerosing cholangitis,~* Infectious diarrhea,~* Signs of intestinal obstruction or perforation or abscess,~* New fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare,~* Increased activity of pre-existing anal or rectal Crohn's disease as part of the flare~* Allergy or sensitivity to salicylates~* Pregnancy or breast-feeding~* Failure of a woman of child-bearing age to agree to use adequate contraception for the 4 week period of the trial, if sexually active~* Severe renal or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
- P (Type: PLACEBO_COMPARATOR): One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).